PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Mercaptopurine

Drugs in development · updated 30 October 2026

Mercaptopurine: clinical trials and development status

Other names and codes: Purinethol, Purixan, Loulla

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 9 March 2012

As of 30 October 2026 Mercaptopurine is in 45 active clinical trials (recruiting or ongoing, phases I–III) for 16 diseases. The most advanced phase is III.

45Active trials
IIIMost advanced phase
16Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Mercaptopurine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Precursor lymphoblastic lymphoma/leukemiaIII19NCT03007147
Burkitt lymphomaIII16NCT02101853
Acute biphenotypic leukaemiaIII6NCT03007147
Precursor T-cell lymphoblastic leukemiaIII6NCT02112916
LeukemiaII–III4NCT03117751
Precursor B-cell lymphoblastic leukemiaIII4NCT03914625
Down syndromeIII3NCT03914625
LymphomaII–III2NCT07072585
Langerhans-cell histiocytosisII–III1NCT02205762
Acute myeloid leukemiaI–II2NCT06199557
Blastic plasmacytoid dendritic cell neoplasmII1NCT04216524
Myelodysplastic SyndromesI–II1NCT06199557
NeoplasmII1NCT03286634
T-cell lymphomaII1NCT06390319
Hereditary leiomyomatosis and renal cell cancer syndromeI1NCT07716735
Renal cell carcinomaI1NCT07716735

Everything on Mercaptopurine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch